JP2016503070A - 免疫寛容剤と併用してｐｐｉを利用する糖尿病を有する患者の間でのインスリン非依存性 - Google Patents

免疫寛容剤と併用してｐｐｉを利用する糖尿病を有する患者の間でのインスリン非依存性 Download PDF

Info

Publication number
JP2016503070A
JP2016503070A JP2015551668A JP2015551668A JP2016503070A JP 2016503070 A JP2016503070 A JP 2016503070A JP 2015551668 A JP2015551668 A JP 2015551668A JP 2015551668 A JP2015551668 A JP 2015551668A JP 2016503070 A JP2016503070 A JP 2016503070A
Authority
JP
Japan
Prior art keywords
diabetes
beta
cells
type
insulin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2015551668A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016503070A5 (https=
Inventor
レヴェタン クラレッサ
レヴェタン クラレッサ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Claresa Levetan
Original Assignee
Claresa Levetan
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Claresa Levetan filed Critical Claresa Levetan
Priority claimed from PCT/US2013/061972 external-priority patent/WO2014052625A1/en
Publication of JP2016503070A publication Critical patent/JP2016503070A/ja
Publication of JP2016503070A5 publication Critical patent/JP2016503070A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/37—Digestive system
    • A61K35/39—Pancreas; Islets of Langerhans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0676—Pancreatic cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/40—Regulators of development

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Wood Science & Technology (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Physiology (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Developmental Biology & Embryology (AREA)
  • General Engineering & Computer Science (AREA)
  • Nutrition Science (AREA)
  • Biochemistry (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Materials For Medical Uses (AREA)
JP2015551668A 2013-01-04 2013-09-26 免疫寛容剤と併用してｐｐｉを利用する糖尿病を有する患者の間でのインスリン非依存性 Pending JP2016503070A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361749197P 2013-01-04 2013-01-04
US61/749,197 2013-01-04
PCT/US2013/061972 WO2014052625A1 (en) 2012-09-27 2013-09-26 Insulin independence among patients with diabetes utilizing a ppi in combination with an immune tolerance agent

Publications (2)

Publication Number Publication Date
JP2016503070A true JP2016503070A (ja) 2016-02-01
JP2016503070A5 JP2016503070A5 (https=) 2016-11-10

Family

ID=54250581

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015551668A Pending JP2016503070A (ja) 2013-01-04 2013-09-26 免疫寛容剤と併用してｐｐｉを利用する糖尿病を有する患者の間でのインスリン非依存性

Country Status (2)

Country Link
EP (1) EP2941250A4 (https=)
JP (1) JP2016503070A (https=)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017155053A1 (ja) * 2016-03-09 2017-09-14 公立大学法人和歌山県立医科大学 非アルコール性脂肪性肝疾患／非アルコール性脂肪性肝炎の治療剤
US9830340B2 (en) 2010-09-23 2017-11-28 Salesforce.Com, Inc. Methods and apparatus for suppressing network feed activities using an information feed in an on-demand database service environment
US10198484B2 (en) 2015-09-10 2019-02-05 Salesforce.Com, Inc. Displaying reduced and detailed visual representations of calendar items based on mouse cursor movement
US10379724B2 (en) 2013-10-28 2019-08-13 Salesforce.Com, Inc. Providing a user interface for customizing state transitions of panes in a bounding window
US10970468B2 (en) 2013-03-15 2021-04-06 Salesforce.Com, Inc. Systems and methods for creating custom actions

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008545712A (ja) * 2005-05-25 2008-12-18 キュアーディーエム、インク． ペプチド、その誘導体並びに類似体、及びそれらを使用する方法

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008545712A (ja) * 2005-05-25 2008-12-18 キュアーディーエム、インク． ペプチド、その誘導体並びに類似体、及びそれらを使用する方法

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
ＣＡＳＥ ＲＥＰＯＲＴＳ ＩＮ ＥＮＤＯＣＲＩＮＯＬＯＧＹ, vol. 2012, JPN6017027004, 2012, pages 468609, ISSN: 0003778953 *
ＥＮＤＯＣＲＩＮＥ ＰＲＡＣＴＩＣＥ, vol. 14, no. 9, JPN6017026999, 2008, pages 1075 - 1083, ISSN: 0003778951 *
ＥＮＤＯＣＲＩＮＥ, vol. [online], JPN6017027003, 12 August 2012 (2012-08-12), pages 10 - 1007, ISSN: 0003778952 *
ＪＯＵＲＮＡＬ ＯＦ ＴＨＥ ＡＭＥＲＩＣＡＮ ＢＯＡＲＤ ＯＦ ＦＡＭＩＬＹ ＭＥＤＩＣＩＮＥ （, vol. 25, no. 1, JPN6017027005, 2012, pages 50 - 54, ISSN: 0003778954 *
ＰＥＰＴＩＤＥＳ, vol. 30, no. 12, JPN6017026997, 2009, pages 2242 - 2249, ISSN: 0003778950 *
日本内科学会雑誌, vol. 98, no. 4, JPN6017026995, 2009, pages 817 - 823, ISSN: 0003778949 *
糖尿病, vol. 54, no. 4, JPN6017027009, 2011, pages 260 - 262, ISSN: 0003778955 *

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9830340B2 (en) 2010-09-23 2017-11-28 Salesforce.Com, Inc. Methods and apparatus for suppressing network feed activities using an information feed in an on-demand database service environment
US10970468B2 (en) 2013-03-15 2021-04-06 Salesforce.Com, Inc. Systems and methods for creating custom actions
US10379724B2 (en) 2013-10-28 2019-08-13 Salesforce.Com, Inc. Providing a user interface for customizing state transitions of panes in a bounding window
US10198484B2 (en) 2015-09-10 2019-02-05 Salesforce.Com, Inc. Displaying reduced and detailed visual representations of calendar items based on mouse cursor movement
WO2017155053A1 (ja) * 2016-03-09 2017-09-14 公立大学法人和歌山県立医科大学 非アルコール性脂肪性肝疾患／非アルコール性脂肪性肝炎の治療剤

Also Published As

Publication number Publication date
EP2941250A4 (en) 2016-07-27
EP2941250A1 (en) 2015-11-11

Similar Documents

Publication Publication Date Title
CN100360182C (zh) 抗原特异性免疫耐受的诱导
ES2334268T3 (es) Procedimientos y composiciones para el tratamiento de la diabetes.
AU2022202003B2 (en) Novel combinations for antigen based therapy
US10080747B2 (en) Nicotinic attenuation of CNS inflammation and autoimmunity
JP2016503070A (ja) 免疫寛容剤と併用してｐｐｉを利用する糖尿病を有する患者の間でのインスリン非依存性
US20150174111A1 (en) Insulin independence among patients with diabetes utilizing a ppi in combination with an immune tolerance agent
US20140234405A1 (en) Insulin independence among patients with diabetes utilizing a ppi in combination with an immune tolerance agent
US8808689B1 (en) Insulin independence among patients with diabetes utilizing a PPI in combination with an immune tolerance agent
JP2017517561A (ja) 最適化ハムスターｒｅｇ３ガンマペプチドを利用する糖尿病を有する患者の間でのインスリン非依存性
WO2014052625A1 (en) Insulin independence among patients with diabetes utilizing a ppi in combination with an immune tolerance agent
US20220088010A1 (en) Co-Administration of inhibitors to produce insulin producing gut cells
WO2004080476A1 (en) Use of secretin in the treatment of schizophrenia
US12605432B2 (en) Combinations for antigen based therapy
RU2824503C2 (ru) Новые комбинации для антигенной терапии
HK40043801A (en) Novel combinations for antigen based therapy
HK1232792A1 (en) Glutamic acid decarboxylase (gad) for use in the treatment of an autoimmune disease
HK1232792B (en) Glutamic acid decarboxylase (gad) for use in the treatment of an autoimmune disease
AU2003223252A1 (en) Method for control of depression using c terminal growth hormone (gh) fragment

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160920

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20160920

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20170725

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20180417